Share this Article
HC Tan, A Low, KS Ng, B Budiono, A Sutandar, BL Chia, YT Lim
Correspondence: Dr Tan Huay Cheem, email@example.com
The increased bleeding risk associated with the use of abciximab has been well reported. The risk appears to be amplified when abciximab is administered concurrently with a fibrinolytic agent. We report and review the literature on the occurrence of a case of fatal pulmonary haemorrhage, a rare bleeding complication, in a patient who received both these drugs.
Keywords: abciximab, fibrinolytic, angioplasty, pulmonary haemorrhage
Singapore Med J 2002; 43(11): 587-589